Equivalência e avaliação da necessidade de sorologia de controle entre esquemas de pré-exposição à raiva humana

Abstract

Serology after the third dose can be considered unnecessary in unexposed patients, since 97% and 100% of volunteers respectively vaccinated by the intradermal and intramuscular route presented satisfactory antibody levels (> 0.5% IU/mL).

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

“…There were 11 citations identified that reported immunogenicity data following ID PVRV for PrEP [16,[20][21][22][23][24][25][26][27][28][29]; of these, 6 were undertaken in Thailand [20,23,25,[28][29][30]. The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21].…”

“…Seroconversion rates from day 14 to 56 after the first vaccination and at 1 year across the studies identified were 90-100% and 20-96%, respectively [16,[21][22][23]25,[27][28][29]. The RVNA GMTs reported across the studies irrespective of PrEP regimen (n = 926), including following booster vaccination after one year, are summarized in Figure 2 [16,[20][21][22][23][24][25][26][27][28][29]. The GMT range across studies from day 14 to 56 after the first vaccination was 1.90-14.35 IU/mL decreasing to ≤1.9 IU/mL at 1 year [16,[20][21][22][23]26,29].…”

“…There were 11 citations identified that reported immunogenicity data following ID PVRV for PrEP [16,[20][21][22][23][24][25][26][27][28][29]; of these, 6 were undertaken in Thailand [20,23,25,[28][29][30]. The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21]. The study populations included: children aged < 1 year [24,27]; children aged 12-16 months [29]; children aged 5-12 years [23]; children and adults [25] or where age was not specified (assumed to be children and adults) [26]; and adults [16,[20][21][22]28].…”

“…The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21]. The study populations included: children aged < 1 year [24,27]; children aged 12-16 months [29]; children aged 5-12 years [23]; children and adults [25] or where age was not specified (assumed to be children and adults) [26]; and adults [16,[20][21][22]28]. Details of the studies and immunogenicity data identified are summarized in Table S1 (Supplementary Materials).…”

“…Seroconversion rates from day 14 to 56 after the first vaccination and at 1 year across the studies identified were 90-100% and 20-96%, respectively [16,[21][22][23]25,[27][28][29]. The RVNA GMTs reported across the studies irrespective of PrEP regimen (n = 926), including following booster vaccination after one year, are summarized in Figure 2 [16,20−29].…”